Clinical Trial Update: Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the combination of idarubicin and azacitidine in patients with intermediate-2 or high-risk myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Idamycin (idarubicin)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: High Grade Myelodysplastic Syndrome Lesions | Phase 1, Phase 2 | Status: COMPLETED